Sera Prognostics (SERA) Financials

Sera Prognostics (NASDAQ: SERA) continues to operate with very limited revenue and significant quarterly losses, but its balance sheet remains well capitalized thanks to a large cash and investment position.

For Q1 2026, the company reported just $14,000 in revenue and a $8.4 million net loss. Operating expenses were again the main driver of red ink, with R&D at $3.0 million, SG&A at $4.3 million, and marketing at $2.0 million. That means Sera is still spending heavily relative to sales, which is typical for an early-stage biotech company, but it also means profitability remains far away.

On the positive side, Sera ended Q1 2026 with $4.2 million in cash, $43.2 million in short-term investments, and $39.4 million in long-term investments. Total assets were $93.5 million versus $25.9 million in total liabilities, leaving the company with $67.6 million in equity. That gives Sera a meaningful liquidity cushion as it continues to fund operations.

Cash flow was mixed. The company used $8.8 million in operating cash during the quarter, but it offset that with $9.0 million from investing activities, largely helped by the sale and/or maturity of investments. Net cash increased slightly by $231,000 in the quarter. However, this improvement came from the investment portfolio rather than from the core business.

Looking at the longer trend across the last four years, several patterns stand out:

• Sera has maintained a large liquidity position, with cash and investments still far exceeding liabilities.
• The company’s equity base has grown materially since early 2024, helped by capital raises and retained proceeds from financing activity.
• Quarterly deferred revenue has stayed near $20 million, which may provide some future revenue visibility.
• Investments have been a useful source of funding, as maturities and sales often offset operating cash burn.
• Revenue has remained very small and inconsistent, ranging from zero to only tens of thousands of dollars per quarter.
• Operating expenses have been fairly steady in the $8.8 million to $9.4 million range over the last year.
• The company continues to report negative earnings per share every quarter, reflecting ongoing losses.
• Q1 2026 operating cash burn of $8.8 million shows the core business is still consuming cash quickly.
• Year over year, revenues remain far too small to cover overhead, making the company dependent on its balance sheet.
• Although share count growth has slowed recently, the company has had meaningful dilution risk over the past several years from equity issuance.

Bottom line: Sera Prognostics is still in the development-stage profile familiar to many small biotech investors: minimal revenue, persistent losses, and reliance on its cash and investment portfolio to fund operations. The good news is that the balance sheet is currently strong enough to support that strategy for now. The key question for investors is whether the company can translate its clinical and commercial efforts into meaningful recurring revenue before its cash burn becomes a larger concern.